MiMedx Group, Inc. MDXG
3.25 USD -0.03 (-0.91%)
At closeNov 3, 2026, 4:00 PM EST
3.25 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
3.14 Day range 3.30
3.03 52-week range 7.97
- YTD
- -51.99%
- 1 year
- -56.78%
News
marketbeat.com What MiMedx Group (MDXG) Said on Its Q3 Earnings Call MiMedx Group NASDAQ: MDXG reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The…
seekingalpha.com MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
benzinga.com MiMedx Group Q3 2026 Earnings Call Transcript MiMedx Group (NASDAQ:MDXG) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6…
benzinga.com MiMedx Group Lowers FY2026 Sales Guidance from $260.000M-$290.000M to $250.000M-$260.000M vs $267.018M Est MiMedx Group (NASDAQ:MDXG) lowers FY2026 sales outlook from $260.000 million-$290.000 million to $250.000 million-$260.000 million vs $267.018 million estimate.
benzinga.com MiMedx Group Q3 Adj. EPS $(0.01), Inline, Sales $62.283M Miss $68.553M Estimate MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 106.67 percent decrease over earnings of $0.15 per share from the same…
benzinga.com MiMedx Group Inks $25M License Deal With Undisclosed Wound Care Competitor To Settle Allegations Of Infringement Of MiMedx's Patents MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of
globenewswire.com MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court…
globenewswire.com MIMEDX Announces $25 Million Patent License Agreement MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care…
defenseworld.net Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX) BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on…
globenewswire.com MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026 MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third…
defenseworld.net MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from Analysts MiMedx Group, Inc (NASDAQ: MDXG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com…
defenseworld.net Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
defenseworld.net Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
benzinga.com MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation
globenewswire.com MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
businesswire.com Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
globenewswire.com MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following…
defenseworld.net Deutsche Bank AG Takes $520,000 Position in MiMedx Group, Inc $MDXG Deutsche Bank AG bought a new position in shares of MiMedx Group, Inc (NASDAQ: MDXG) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange…- benzinga.com Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8 Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and raises the price target from $6 to $8.
- benzinga.com Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
businesswire.com Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
benzinga.com Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed financial results.
seekingalpha.com MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
marketbeat.com MiMedx Group Q2 Earnings Call Highlights MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement…
benzinga.com MiMedx Group Affirms FY2026 Sales Guidance of $260.000M-$290.000M vs $269.440M Est MiMedx Group (NASDAQ:MDXG) affirms FY2026 sales outlook from $260.000 million-$290.000 million to $260.000 million-$290.000 million vs $269.440 million estimate.
benzinga.com MiMedx Group Q2 Adj. EPS $(0.05), Inline, Sales $64.362M Beat $63.460M Estimate MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 150 percent decrease over earnings of $0.10 per share from the same…
globenewswire.com MIMEDX Announces Second Quarter 2026 Operating & Financial Results Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July…- benzinga.com MIMEDX Acquires Sanara MedTech For ~$350M Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical SubspecialtiesAccelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly…
globenewswire.com MIMEDX to Acquire Sanara MedTech Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly…
globenewswire.com MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29 MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to…
benzinga.com Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6 Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $7 to $6.- benzinga.com CORRECTION: MiMedx Group Q1 Adj. EPS $(0.05) Misses $(0.03) Estimate, Sales $58.991M Miss $65.020M Estimate. MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 183.33 percent decrease over earnings of…
- benzinga.com MiMedx Group Lowers FY2026 Sales Guidance from $340.000M-$360.000M to $260.000M-$290.000M vs $307.000M Est MiMedx Group (NASDAQ:MDXG) lowers FY2026 sales outlook from $340.000 million-$360.000 million to $260.000 million-$290.000 million vs $307.000 million estimate.
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7 Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $10 to $7.
- benzinga.com Craig-Hallum Maintains Buy on MiMedx Group, Lowers Price Target to $7 Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers the price target from $10 to $7.
benzinga.com MiMedx Group Announces Commercial Launch Of AMNIOFIX Thyroid Shields, Product Line Extension Of AMNIOFIX DHACM Allografts MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human…- benzinga.com MiMedx Group Sees FY2026 Sales $340.000M-$360.000M vs $376.533M Est MiMedx Group (NASDAQ:MDXG) sees FY2026 sales of $340.000 million-$360.000 million vs $376.533 million analyst estimate.
benzinga.com Earnings Summary: MiMedx Group Q4 - benzinga.com MiMedx Group Q4 Adj. EPS $0.14 Beats $0.07 Estimate, Sales $118.095M Beat $106.775M Estimate MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.07 by 94.44 percent. This is a 100 percent increase over earnings of $0.07…
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com What to Expect from MiMedx Group's Earnings - benzinga.com Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock
benzinga.com This MiMedx Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Earnings Scheduled For October 29, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For July 30, 2025